Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Bionano Genomics stock | 0.5

Own Bionano Genomics stock in just a few minutes.


Fact checked

Bionano Genomics, Inc is a diagnostics & research business based in the US. Bionano Genomics shares (BNGO) are listed on the NASDAQ and all prices are listed in US Dollars. Bionano Genomics employs 97 staff and has a trailing 12-month revenue of around USD$8.4 million.

How to buy shares in Bionano Genomics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Bionano Genomics. Find the stock by name or ticker symbol: BNGO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Bionano Genomics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$0.5, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Bionano Genomics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Bionano Genomics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Bionano Genomics's share price?

Since the stock market crash in March caused by coronavirus, Bionano Genomics's share price has had significant negative movement.

Its last market close was USD$0.5, which is 54.95% down on its pre-crash value of USD$1.11 and 28.21% up on the lowest point reached during the March crash when the shares fell as low as USD$0.39.

If you had bought USD$1,000 worth of Bionano Genomics shares at the start of February 2020, those shares would have been worth USD$425.54 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$495.05.

Bionano Genomics share price

Use our graph to track the performance of BNGO stocks over time.

Bionano Genomics shares at a glance

Information last updated 2020-10-19.
Latest market close USD$0.5
52-week range USD$0.25 - USD$1.39
50-day moving average USD$0.5885
200-day moving average USD$0.5397
Wall St. target price USD$1.48
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.759

Buy Bionano Genomics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Bionano Genomics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Bionano Genomics price performance over time

Historical closes compared with the close of $0.5 from 2020-11-16

1 week (2020-11-18) -1.96%
1 month (2020-10-26) -8.16%
3 months (2020-08-25) -25.37%
6 months (2020-05-22) 6.38%
1 year (2019-11-25) -48.18%
2 years (2018-11-22) N/A
3 years (2017-11-22) N/A
5 years (2015-11-22) N/A

Bionano Genomics financials

Revenue TTM USD$8.4 million
Gross profit TTM USD$3.4 million
Return on assets TTM -71.65%
Return on equity TTM -1464.01%
Profit margin 0%
Book value $0.063
Market capitalisation USD$82.9 million

TTM: trailing 12 months

Shorting Bionano Genomics shares

There are currently 5.8 million Bionano Genomics shares held short by investors – that's known as Bionano Genomics's "short interest". This figure is 6.8% up from 5.4 million last month.

There are a few different ways that this level of interest in shorting Bionano Genomics shares can be evaluated.

Bionano Genomics's "short interest ratio" (SIR)

Bionano Genomics's "short interest ratio" (SIR) is the quantity of Bionano Genomics shares currently shorted divided by the average quantity of Bionano Genomics shares traded daily (recently around 7.4 million). Bionano Genomics's SIR currently stands at 0.78. In other words for every 100,000 Bionano Genomics shares traded daily on the market, roughly 780 shares are currently held short.

However Bionano Genomics's short interest can also be evaluated against the total number of Bionano Genomics shares, or, against the total number of tradable Bionano Genomics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bionano Genomics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Bionano Genomics shares in existence, roughly 40 shares are currently held short) or 0.0401% of the tradable shares (for every 100,000 tradable Bionano Genomics shares, roughly 40 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bionano Genomics.

Find out more about how you can short Bionano Genomics stock.

Bionano Genomics share dividends

We're not expecting Bionano Genomics to pay a dividend over the next 12 months.

Bionano Genomics share price volatility

Over the last 12 months, Bionano Genomics's shares have ranged in value from as little as $0.25 up to $1.39. A popular way to gauge a stock's volatility is its "beta".

BNGO.US volatility(beta: 1.54)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bionano Genomics's is 1.544. This would suggest that Bionano Genomics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Bionano Genomics overview

Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system includes an instrument, chip consumables, reagents, and a suite of data analysis tools. The company's Bionano prep kits and labeling kits provide the critical reagents and protocols needed to extract and label high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site